# Immunology and Microbiology

**Type:** Fields  
**Canonical URL:** https://scholariq.org/fields/immunology-and-microbiology/

## Facts

| Field | Value |
| --- | --- |
| Description | Immunology and Microbiology is one of 26 top-level fields in the OpenAlex subject taxonomy. This atlas publishes 43 topics in it, covering 8,293 indexed works. |
| Researchers | 11,248 |
| Subfields | Antimicrobial Peptides and Activities,Aquaculture disease management and microbiota,Atherosclerosis and Cardiovascular Diseases,Bacterial Infections and Vaccines,Bartonella species infections research,Biomarkers in Disease Mechanisms,Biosimilars and Bioanalytical Methods,Bird parasitology and diseases,Complement system in diseases,Galectins and Cancer Biology,HIV Research and Treatment,Antibiotic Use and Resistance |
| Top Institutions | Centre National de la Recherche Scientifique,Harvard University,Chinese Academy of Sciences,University of Washington,Stanford University,Johns Hopkins University,Inserm,National Institutes of Health,University of Michigan,University College London |

## Field papers

Showing 15 of 6764.

- [Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis](https://scholariq.org/papers/global-burden-of-bacterial-antimicrobial-resistance-in-2019-a-systematic/)
- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding](https://scholariq.org/papers/genomic-characterisation-and-epidemiology-of-2019-novel-coronavirus-implications/)
- [Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-advanced-nonsquamous-non-small-cell-lung-cancer/)
- [Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease](https://scholariq.org/papers/antiinflammatory-therapy-with-canakinumab-for-atherosclerotic-disease/)
- [Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer](https://scholariq.org/papers/safety-and-activity-of-anti-pd-l1-antibody-in-patients-with-advanced-cancer/)
- [Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study](https://scholariq.org/papers/global-regional-and-national-sepsis-incidence-and-mortality-1990-2017-analysis/)
- [Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016](https://scholariq.org/papers/surviving-sepsis-campaign-international-guidelines-for-management-of-sepsis-and/)
- [Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis](https://scholariq.org/papers/discovery-research-and-development-of-new-antibiotics-the-who-priority-list-of/)
- [Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease](https://scholariq.org/papers/evolocumab-and-clinical-outcomes-in-patients-with-cardiovascular-disease/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors](https://scholariq.org/papers/gut-microbiome-influences-efficacy-of-pd-1-based-immunotherapy-against/)
- [Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China](https://scholariq.org/papers/dysregulation-of-immune-response-in-patients-with-coronavirus-2019-covid-19-in/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Immune-Related Adverse Events Associated with Immune Checkpoint Blockade](https://scholariq.org/papers/immune-related-adverse-events-associated-with-immune-checkpoint-blockade/)

## Field topics

Showing 24 of 43.

- [Antibiotic Use and Resistance](https://scholariq.org/topics/antibiotic-use-and-resistance/)
- [Antimicrobial Peptides and Activities](https://scholariq.org/topics/antimicrobial-peptides-and-activities/)
- [Aquaculture disease management and microbiota](https://scholariq.org/topics/aquaculture-disease-management-and-microbiota/)
- [Atherosclerosis and Cardiovascular Diseases](https://scholariq.org/topics/atherosclerosis-and-cardiovascular-diseases/)
- [Bacterial Infections and Vaccines](https://scholariq.org/topics/bacterial-infections-and-vaccines/)
- [Bartonella species infections research](https://scholariq.org/topics/bartonella-species-infections-research/)
- [Biomarkers in Disease Mechanisms](https://scholariq.org/topics/biomarkers-in-disease-mechanisms/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Bird parasitology and diseases](https://scholariq.org/topics/bird-parasitology-and-diseases/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Galectins and Cancer Biology](https://scholariq.org/topics/galectins-and-cancer-biology/)
- [HIV Research and Treatment](https://scholariq.org/topics/hiv-research-and-treatment/)
- [IL-33, ST2, and ILC Pathways](https://scholariq.org/topics/il-33-st2-and-ilc-pathways/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)
- [Immune Response and Inflammation](https://scholariq.org/topics/immune-response-and-inflammation/)
- [Immune responses and vaccinations](https://scholariq.org/topics/immune-responses-and-vaccinations/)
- [Immunodeficiency and Autoimmune Disorders](https://scholariq.org/topics/immunodeficiency-and-autoimmune-disorders/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Immunotoxicology and immune responses](https://scholariq.org/topics/immunotoxicology-and-immune-responses/)
- [Inflammation biomarkers and pathways](https://scholariq.org/topics/inflammation-biomarkers-and-pathways/)
- [interferon and immune responses](https://scholariq.org/topics/interferon-and-immune-responses/)
- [Invertebrate Immune Response Mechanisms](https://scholariq.org/topics/invertebrate-immune-response-mechanisms/)
- [Leptospirosis research and findings](https://scholariq.org/topics/leptospirosis-research-and-findings/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.